Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Role of allo-SCT for CML in 2010

Bone Marrow Transplantation volume 45, pages 1579–1586 (2010)Cite this article

Subjects

Abstract

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of CML. However, for a minority of patients who fail TKI or progress to advanced phase disease, allo-SCT remains the only therapeutic option. This review addresses the current indications for allo-SCT in CML and the role of conditioning (myeloablative vs reduced intensity), donor source (sibling vs volunteer unrelated donor), graft source (BM vs peripheral blood vs cord) and the value of pre-, peri- and post transplant use of TKI in the management of CML.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Pavlovsky C, Kantarjian H, Cortes JE . First-line therapy for chronic myeloid leukemia: past, present, and future. Am J Hematol 2009; 84: 287–293.

    CAS  PubMed  Google Scholar 

  2. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91: 513–521.

    PubMed  Google Scholar 

  3. Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007; 109: 5143–5150.

    CAS  PubMed  Google Scholar 

  4. Deininger M, Schleuning M, Greinix H, Sayer HG, Fischer T, Martinez J et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 2006; 91: 452–459.

    CAS  PubMed  Google Scholar 

  5. Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 2006; 108: 1421–1423.

    CAS  PubMed  Google Scholar 

  6. Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 2008; 112: 3500–3507.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Oehler VG, Gooley T, Snyder DS, Johnston L, Lin A, Cummings CC et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007; 109: 1782–1789.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Weisser M, Schleuning M, Haferlach C, Schwerdtfeger R, Kolb HJ . Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy. Leuk Lymphoma 2007; 48: 295–301.

    CAS  PubMed  Google Scholar 

  9. Zaucha JM, Prejzner W, Giebel S, Gooley TA, Szatkowski D, Kalwak K et al. Imatinib therapy prior to myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 36: 417–424.

    CAS  PubMed  Google Scholar 

  10. Maziarz RT . Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors? Curr Opin Hematol 2008; 15: 127–133.

    CAS  PubMed  Google Scholar 

  11. O'Brien S, Berman E, Borghaei H, DeAngelo DJ, Devetten MP, Devine S et al. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw 2009; 7: 984–1023.

    PubMed  Google Scholar 

  12. European LeukemiaNet Update. Recommendations from the European LeukemiaNet for the Management of chronic myeloid leukemia (CML). 2010. Available from: http://www.leukemia-net.org/content/leukemias/cml/recommendations/.

  13. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. chronic leukemia working party of the European group for blood and marrow transplantation. Lancet 1998; 352: 1087–1092.

    CAS  PubMed  Google Scholar 

  14. Hochhaus A, O′Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054–1061.

    CAS  PubMed  Google Scholar 

  15. Deininger Mea. Abstract 1126 (therapy poster I): International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. (ASH 2009) 2009.

  16. Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 2007; 109: 4686–4692.

    CAS  PubMed  Google Scholar 

  17. Jabbour E, Jones D, Kantarjian HM, O′Brien S, Tam C, Koller C et al. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 2009; 114: 2037–2043.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Muller MC, Cortes JE, Kim DW, Druker BJ, Erben P, Pasquini R et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 2009; 114: 4944–4953.

    PubMed  PubMed Central  Google Scholar 

  19. Milojkovic D, Nicholson E, Apperley JF, Holyoake TL, Shepherd P, Drummond MW et al. Early prediction of success or failure using second generation tyrosine kinase inhibitors for chronic myeloid leukemia. Haematologica 2010; 95: 224–231.

    CAS  PubMed  Google Scholar 

  20. Kantarjian HM, Cortes J, O′Brien S, Giles FJ, Albitar M, Rios MB et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002; 99: 3547–3553.

    CAS  PubMed  Google Scholar 

  21. Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005; 23: 5074–5087.

    Google Scholar 

  22. Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000; 95: 3702–3709.

    CAS  PubMed  Google Scholar 

  23. Elmaagacli AH, Basoglu S, Peceny R, Trenschel R, Ottinger H, Lollert A et al. Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood 2002; 99: 1130–1135.

    CAS  PubMed  Google Scholar 

  24. Oehler VG, Radich JP, Storer B, Blume KG, Chauncey T, Clift R et al. Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. Biol Blood Marrow Transplant 2005; 11: 85–92.

    PubMed  Google Scholar 

  25. Meisel R, Laws HJ, Balzer S, Bernbeck B, Kramm C, Schonberger S et al. Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies. Biol Blood Marrow Transplant 2007; 13: 1338–1345.

    PubMed  Google Scholar 

  26. Remberger M, Ringden O, Blau IW, Ottinger H, Kremens B, Kiehl MG et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 2001; 98: 1739–1745.

    CAS  PubMed  Google Scholar 

  27. Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 1997; 337: 373–381.

    Article  CAS  PubMed  Google Scholar 

  28. Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998; 339: 1565–1577.

    Article  CAS  PubMed  Google Scholar 

  29. Sanz GF, Saavedra S, Jimenez C, Senent L, Cervera J, Planelles D et al. Unrelated donor cord blood transplantation in adults with chronic myelogenous leukemia: results in nine patients from a single institution. Bone Marrow Transplant 2001; 27: 693–701.

    CAS  PubMed  Google Scholar 

  30. Nagamura-Inoue T, Kai S, Azuma H, Takanashi M, Isoyama K, Kato K et al. Unrelated cord blood transplantation in CML: Japan Cord Blood Bank Network analysis. Bone Marrow Transplant 2008; 42: 241–251.

    CAS  PubMed  Google Scholar 

  31. Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997; 15: 1767–1777.

    CAS  PubMed  Google Scholar 

  32. Weisdorf DJ, Anasetti C, Antin JH, Kernan NA, Kollman C, Snyder D et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 2002; 99: 1971–1977.

    CAS  PubMed  Google Scholar 

  33. Weisdorf DJ, Nelson G, Lee SJ, Haagenson M, Spellman S, Antin JH et al. Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse. Biol Blood Marrow Transplant 2009; 15: 1475–1478.

    PubMed  PubMed Central  Google Scholar 

  34. Arora M, Weisdorf DJ, Spellman SR, Haagenson MD, Klein JP, Hurley CK et al. HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. J Clin Oncol 2009; 27: 1644–1652.

    PubMed  PubMed Central  Google Scholar 

  35. Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004; 104: 1923–1930.

    CAS  PubMed  Google Scholar 

  36. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576–4583.

    CAS  PubMed  Google Scholar 

  37. Clift RA, Buckner CD, Appelbaum FR, Bryant E, Bearman SI, Petersen FB et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 1991; 77: 1660–1665.

    CAS  PubMed  Google Scholar 

  38. Porter DL, Collins Jr RH, Hardy C, Kernan NA, Drobyski WR, Giralt S et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000; 95: 1214–1221.

    CAS  PubMed  Google Scholar 

  39. Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005; 106: 2969–2976.

    CAS  PubMed  Google Scholar 

  40. Kebriaei P, Detry MA, Giralt S, Carrasco-Yalan A, Anagnostopoulos A, Couriel D et al. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood 2007; 110: 3456–3462.

    CAS  PubMed  Google Scholar 

  41. Kerbauy FR, Storb R, Hegenbart U, Gooley T, Shizuru J, Al-Ali HK et al. Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. Leukemia 2005; 19: 990–997.

    CAS  PubMed  Google Scholar 

  42. Krejci M, Mayer J, Doubek M, Brychtova Y, Pospisil Z, Racil Z et al. Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia. Bone Marrow Transplant 2006; 38: 483–491.

    CAS  PubMed  Google Scholar 

  43. Liu QF, Fan ZP, Zhang Y, Jiang ZJ, Wang CY, Xu D et al. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia. Biol Blood Marrow Transplant 2009; 15: 1376–1385.

    CAS  PubMed  Google Scholar 

  44. Luo Y, Lai XY, Tan YM, Shi JM, Zhao YM, Han XY et al. Reduced-intensity allogeneic transplantation combined with imatinib mesylate for chronic myeloid leukemia in first chronic phase. Leukemia 2009; 23: 1171–1174.

    CAS  PubMed  Google Scholar 

  45. Olavarria E, Siddique S, Griffiths MJ, Avery S, Byrne JL, Piper KP et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 2007; 110: 4614–4617.

    CAS  PubMed  Google Scholar 

  46. Or R, Shapira MY, Resnick I, Amar A, Ackerstein A, Samuel S et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003; 101: 441–445.

    CAS  PubMed  Google Scholar 

  47. Ruiz-Arguelles GJ, Gomez-Almaguer D, Morales-Toquero A, Gutierrez-Aguirre CH, Vela-Ojeda J, Garcia-Ruiz-Esparza MA et al. The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplant 2005; 36: 1043–1047.

    CAS  PubMed  Google Scholar 

  48. Weisser M, Schleuning M, Ledderose G, Rolf B, Schnittger S, Schoch C et al. Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease. Bone Marrow Transplant 2004; 34: 1083–1088.

    CAS  PubMed  Google Scholar 

  49. Bacher U, Klyuchnikov E, Zabelina T, Ottinger H, Beelen DW, Schrezenmeier H et al. The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia-a report from the German Registry covering the period from 1998 to 2004. Ann Hematol 2009; 88: 1237–1247.

    PubMed  Google Scholar 

  50. Bornhauser M, Kroger N, Schwerdtfeger R, Schafer-Eckart K, Sayer HG, Scheid C et al. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study. Eur J Haematol 2006; 76: 9–17.

    PubMed  Google Scholar 

  51. Burke MJ, Trotz B, Luo X, Weisdorf DJ, Baker KS, Wagner JE et al. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients. Bone Marrow Transplant 2009; 44: 169–174.

    CAS  PubMed  Google Scholar 

  52. Chen MH, Chiou TJ, Lin PC, Gau JP, Hsu HC, Hsiao LT et al. Comparison of myeloablative and nonmyeloablative hematopoietic stem cell transplantation for treatment of chronic myeloid leukemia. Int J Hematol 2007; 86: 275–281.

    CAS  PubMed  Google Scholar 

  53. Holowiecki J, Giebel S, Wojnar J, Krawczyk-Kulis M, Markiewicz M, Holowiecka-Goral A et al. Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia. Br J Haematol 2008; 142: 284–292.

    CAS  PubMed  Google Scholar 

  54. Kojima R, Kami M, Kanda Y, Kusumi E, Kishi Y, Tanaka Y et al. Comparison between reduced intensity and conventional myeloablative allogeneic stem-cell transplantation in patients with hematologic malignancies aged between 50 and 59 years. Bone Marrow Transplant 2005; 36: 667–674.

    CAS  PubMed  Google Scholar 

  55. Le Blanc K, Barrett AJ, Schaffer M, Hagglund H, Ljungman P, Ringden O et al. Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies. Biol Blood Marrow Transplant 2009; 15: 1108–1115.

    PubMed  PubMed Central  Google Scholar 

  56. Linn YC, Phang CY, Lim TJ, Chong SF, Heng KK, Lee JJ et al. Effect of missing killer-immunoglobulin-like receptor ligand in recipients undergoing HLA full matched, non-T-depleted sibling donor transplantation: a single institution experience of 151 Asian patients. Bone Marrow Transplant 2010; 45: 1031–1037.

    CAS  PubMed  Google Scholar 

  57. Radich JP, Gooley T, Bensinger W, Chauncey T, Clift R, Flowers M et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003; 102: 31–35.

    CAS  PubMed  Google Scholar 

  58. Ringden O, Pavletic SZ, Anasetti C, Barrett AJ, Wang T, Wang D et al. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood 2009; 113: 3110–3118.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Russell JA, Duan Q, Chaudhry MA, Savoie ML, Balogh A, Turner AR et al. Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease. Biol Blood Marrow Transplant 2008; 14: 888–895.

    CAS  PubMed  Google Scholar 

  60. Valcarcel D, Martino R, Sureda A, Canals C, Altes A, Briones J et al. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Eur J Haematol 2005; 74: 144–151.

    CAS  PubMed  Google Scholar 

  61. Yakoub-Agha I, Mesnil F, Kuentz M, Boiron JM, Ifrah N, Milpied N et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 2006; 24: 5695–5702.

    PubMed  Google Scholar 

  62. Das M, Saikia TK, Advani SH, Parikh PM, Tawde S . Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia. Bone Marrow Transplant 2003; 32: 125–129.

    CAS  PubMed  Google Scholar 

  63. Dazzi F, Fozza C . Disease relapse after haematopoietic stem cell transplantation: risk factors and treatment. Best Pract Res Clin Haematol 2007; 20: 311–327.

    CAS  PubMed  Google Scholar 

  64. Kantarjian HM, O′Brien S, Cortes JE, Giralt SA, Rios MB, Shan J et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002; 100: 1590–1595.

    CAS  PubMed  Google Scholar 

  65. Carpenter PA, Snyder DS, Flowers ME, Sanders JE, Gooley TA, Martin PJ et al. Prophylactic administration of imatinib after hematopoietic cell tran.splantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007; 109: 2791–2793.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Klyuchnikov E, Kroger N, Brummendorf TH, Wiedemann B, Zander AR, Bacher U . Current status and perspectives of tyrosine kinase inhibitor treatment in the post-transplant period in patients with chronic myeloid leukemia (CML). Biol Blood Marrow Transplant 2010; 16: 301–310.

    CAS  PubMed  Google Scholar 

  67. Klyuchnikov E, Schafhausen P, Kroger N, Brummendorf TH, Osanmaz O, Asenova S et al. Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. Acta Haematol 2009; 122: 6–10.

    PubMed  Google Scholar 

  68. Wright MP, Shepherd JD, Barnett MJ, Nantel SH, Sutherland HJ, Toze CL et al. Response to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16: 639–646.

    CAS  PubMed  Google Scholar 

  69. Olavarria E, Ottmann OG, Deininger M, Clark RE, Bandini G, Byrne J et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2003; 17: 1707–1712.

    CAS  PubMed  Google Scholar 

  70. Hess G, Bunjes D, Siegert W, Schwerdtfeger R, Ledderose G, Wassmann B et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol 2005; 23: 7583–7593.

    CAS  PubMed  Google Scholar 

  71. Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58–60.

    CAS  PubMed  Google Scholar 

  72. Palandri F, Amabile M, Rosti G, Bandini G, Benedetti F, Usala E et al. Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. Bone Marrow Transplant 2007; 39: 189–191.

    CAS  PubMed  Google Scholar 

  73. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319–325.

    CAS  PubMed  Google Scholar 

  74. Collins Jr RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433–444.

    PubMed  Google Scholar 

  75. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041–2050.

    CAS  PubMed  Google Scholar 

  76. Porter D, Levine JE . Graft-versus-host disease and graft-versus-leukemia after donor leukocyte infusion. Semin Hematol 2006; 43: 53–61.

    PubMed  Google Scholar 

  77. Raiola AM, Van Lint MT, Valbonesi M, Lamparelli T, Gualandi F, Occhini D et al. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplant 2003; 31: 687–693.

    CAS  PubMed  Google Scholar 

  78. Dazzi F, Szydlo RM, Craddock C, Cross NC, Kaeda J, Chase A et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000; 95: 67–71.

    CAS  PubMed  Google Scholar 

  79. Savani BN, Montero A, Kurlander R, Childs R, Hensel N, Barrett AJ . Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 36: 1009–1015.

    CAS  PubMed  Google Scholar 

  80. Jabbour E, Cortes JE, Giles FJ, O'Brien S, Kantarjian HM . Current and emerging treatment options in chronic myeloid leukemia. Cancer 2007; 109: 2171–2181.

    CAS  PubMed  Google Scholar 

  81. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908–916.

    PubMed  Google Scholar 

  82. Atallah E, Durand JB, Kantarjian H, Cortes J . Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007; 110: 1233–1237.

    CAS  PubMed  Google Scholar 

  83. Gambacorti-Passerini C, Tornaghi L, Franceschino A, Piazza R, Corneo G, Pogliani E . In reply to ′Cardiotoxicity of the cancer therapeutic agent imatinib mesylate′. Nat Med 2007; 13: 13–14, author reply 5–6.

    PubMed  Google Scholar 

  84. Sohn SK, Kim JG, Kim DH, Lee KB . Cardiac morbidity in advanced chronic myelogenous leukaemia patients treated by successive allogeneic stem cell transplantation with busulphan/cyclophosphamide conditioning after imatinib mesylate administration. Br J Haematol 2003; 121: 469–472.

    PubMed  Google Scholar 

  85. Mauro MJ, Deininger MW . Management of drug toxicities in chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009; 22: 409–429.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Department of Medicine, Hematology and Stem Cell Transplantation Section, Vanderbilt University Medical Center, Nashville, TN, USA

    N Venepalli & B N Savani

  2. Departments of Hematology, Hammersmith Hospitals Trust, Imperial College London, London, UK

    K Rezvani

  3. Division of Hematology and Oncology, Department of Internal Medicine II, Allogeneic Stem Cell Transplant Center, Julius Maximilian University, Würzburg, Germany

    S Mielke

Authors
  1. N Venepalli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Rezvani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Mielke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B N Savani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B N Savani.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Venepalli, N., Rezvani, K., Mielke, S. et al. Role of allo-SCT for CML in 2010. Bone Marrow Transplant 45, 1579–1586 (2010). https://doi.org/10.1038/bmt.2010.138

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.138

Keywords

This article is cited by

Search

Advanced search

Quick links